Been a busy weekend and just now catching up. Great DD Chanel5, thanks for sharing!
Considering Ken Mayer's background (ElectroTherapeutics, HealthCheck, SAFE Health), let’s map out a step‑by‑step collaboration roadmap showing how he could help BIEL Corp evolve from a niche wearable pain‑relief company into a fully integrated bioelectronic medicine leader.
Collaboration Roadmap: Ken Mayer × BIEL Corp
Short‑Term (0–12 months)
Technology Alignment
Integrate Mayer’s connected diagnostics system with BIEL’s wearable devices (ActiPatch, RecoveryRx, etc.) to enable real‑time monitoring of pain and healing outcomes.
Begin pilot programs where BIEL devices feed data into HealthCheck’s telehealth platform, making them reimbursable and clinically trackable.
Clinical Validation
Use SAFE Health’s Mayo Clinic partnership to run population‑scale studies validating BIEL’s devices as cost‑effective alternatives to opioids and invasive procedures.
Strengthen FDA and insurance reimbursement pathways with Mayer’s infrastructure expertise.
Mid‑Term (1–3 years)
Programmable Therapeutics
Collaborate with ElectroTherapeutics to evolve BIEL’s static devices into programmable bioelectric therapeutics, capable of adjusting stimulation patterns based on patient data.
Launch a connected electroceutical portfolio where BIEL’s devices are part of a broader therapeutic ecosystem.
Telehealth Integration
Position BIEL’s products as standard tools in telehealth pain management kits, bundled with HealthCheck’s reimbursable diagnostics.
Enable remote physicians to prescribe, monitor, and adjust BIEL devices through Mayer’s connected platforms.
Global Expansion
Leverage Mayer’s networks to expand BIEL’s distribution beyond Spain and Mexico into North America, Europe, and Asia, targeting health systems adopting digital therapeutics.
Long‑Term (3–7 years)
National Healthcare Infrastructure
Embed BIEL’s devices into national healthcare infrastructure as reimbursable, first‑line therapies for chronic pain, wound healing, and recovery.
Position BIEL as a population‑scale solution provider, reducing healthcare costs by replacing drugs and surgeries with bioelectronic medicine.
Portfolio Diversification
Develop multi‑condition electroceuticals (e.g., for arthritis, neuropathy, post‑surgical recovery) using Mayer’s programmable platform.
Expand into animal health with HealFast, integrated into veterinary telehealth systems.
Thought Leadership
Establish BIEL + Mayer as global leaders in bioelectronic medicine, shaping policy, reimbursement, and clinical adoption.
Publish joint research with Mayo Clinic and SAFE Health to cement credibility.
Potential Impact
Revenue Growth: New reimbursement pathways + telehealth integration.
Innovation Leap: Programmable therapeutics elevate BIEL’s devices beyond static wearables.
Healthcare Transformation: BIEL becomes part of national infrastructure, reducing costs at scale.
Global Leadership: Jointly position as pioneers of bioelectronic medicine.
In essence, Ken Mayer could turn BIEL Corp into the “Intel inside” of bioelectronic medicine — powering connected, programmable, reimbursable devices across telehealth, hospitals, and national healthcare systems.
Considering Ken Mayer's background (ElectroTherapeutics, HealthCheck, SAFE Health), let’s map out a step‑by‑step collaboration roadmap showing how he could help BIEL Corp evolve from a niche wearable pain‑relief company into a fully integrated bioelectronic medicine leader.
Collaboration Roadmap: Ken Mayer × BIEL Corp
Short‑Term (0–12 months)
Technology Alignment
Integrate Mayer’s connected diagnostics system with BIEL’s wearable devices (ActiPatch, RecoveryRx, etc.) to enable real‑time monitoring of pain and healing outcomes.
Begin pilot programs where BIEL devices feed data into HealthCheck’s telehealth platform, making them reimbursable and clinically trackable.
Clinical Validation
Use SAFE Health’s Mayo Clinic partnership to run population‑scale studies validating BIEL’s devices as cost‑effective alternatives to opioids and invasive procedures.
Strengthen FDA and insurance reimbursement pathways with Mayer’s infrastructure expertise.
Mid‑Term (1–3 years)
Programmable Therapeutics
Collaborate with ElectroTherapeutics to evolve BIEL’s static devices into programmable bioelectric therapeutics, capable of adjusting stimulation patterns based on patient data.
Launch a connected electroceutical portfolio where BIEL’s devices are part of a broader therapeutic ecosystem.
Telehealth Integration
Position BIEL’s products as standard tools in telehealth pain management kits, bundled with HealthCheck’s reimbursable diagnostics.
Enable remote physicians to prescribe, monitor, and adjust BIEL devices through Mayer’s connected platforms.
Global Expansion
Leverage Mayer’s networks to expand BIEL’s distribution beyond Spain and Mexico into North America, Europe, and Asia, targeting health systems adopting digital therapeutics.
Long‑Term (3–7 years)
National Healthcare Infrastructure
Embed BIEL’s devices into national healthcare infrastructure as reimbursable, first‑line therapies for chronic pain, wound healing, and recovery.
Position BIEL as a population‑scale solution provider, reducing healthcare costs by replacing drugs and surgeries with bioelectronic medicine.
Portfolio Diversification
Develop multi‑condition electroceuticals (e.g., for arthritis, neuropathy, post‑surgical recovery) using Mayer’s programmable platform.
Expand into animal health with HealFast, integrated into veterinary telehealth systems.
Thought Leadership
Establish BIEL + Mayer as global leaders in bioelectronic medicine, shaping policy, reimbursement, and clinical adoption.
Publish joint research with Mayo Clinic and SAFE Health to cement credibility.
Potential Impact
Revenue Growth: New reimbursement pathways + telehealth integration.
Innovation Leap: Programmable therapeutics elevate BIEL’s devices beyond static wearables.
Healthcare Transformation: BIEL becomes part of national infrastructure, reducing costs at scale.
Global Leadership: Jointly position as pioneers of bioelectronic medicine.
In essence, Ken Mayer could turn BIEL Corp into the “Intel inside” of bioelectronic medicine — powering connected, programmable, reimbursable devices across telehealth, hospitals, and national healthcare systems.
2
